---
layout: minimal-medicine
title: Vemurafenib
---

# Vemurafenib
### Generic Name
Vemurafenib

### Usage

Vemurafenib is a targeted therapy primarily used to treat unresectable or metastatic melanoma (skin cancer) with a specific mutation in the *BRAF* gene called the V600E mutation.  This means the medication is only effective in patients whose melanoma has this particular genetic alteration, which should be confirmed through an FDA-approved test before treatment begins.  It's crucial to understand that Vemurafenib is not effective against melanoma without this *BRAF* V600E mutation.  Additionally, Vemurafenib is also approved for treating Erdheim-Chester disease, a rare disorder, when it's associated with the *BRAF* V600 mutation.  While sometimes used off-label in combination with other medications for other BRAF mutations (like V600K) or in combination therapies for melanoma, these uses are not officially endorsed by regulatory agencies.

### Dosage

The typical adult dosage of Vemurafenib is 960 mg taken orally twice daily (every 12 hours).  This dosage remains consistent for both melanoma and Erdheim-Chester disease, contingent on the presence of the *BRAF* V600 mutation. Treatment continues until the disease progresses or unacceptable side effects occur.  The medication comes in tablet form.  

**Important Dosage Adjustments:**  Dosage adjustments are crucial based on several factors including toxicity and interactions with other drugs.  For example, if a patient experiences intolerable side effects, the dose might be reduced to 720 mg BID (twice daily), and further reduced to 480 mg BID if side effects persist.  Severe side effects will necessitate discontinuation. Concomitant use with strong CYP3A4 inducers requires dose increases, while the absence of these drugs requires careful readjustment. Dosage adjustments are not standardized for hepatic or renal impairment, necessitating careful clinical monitoring.   No pediatric dosing information is available as safety and effectiveness haven't been established in children.

### Side Effects

**Common Side Effects (>10%):**

*   Fatigue
*   Rash (maculopapular rash, hyperkeratosis)
*   Peripheral neuropathy (numbness, tingling in extremities)
*   Headache
*   Diarrhea
*   Nausea
*   Vomiting
*   Decreased appetite
*   Constipation
*   QT prolongation (on electrocardiogram â€“ ECG)
*   Hypertension (high blood pressure)
*   Peripheral edema (swelling)
*   Cough
*   Arthralgia (joint pain)
*   Myalgia (muscle pain)
*   Alopecia (hair loss)


**Less Common but Serious Side Effects:**

*   Stevens-Johnson syndrome (severe skin reaction)
*   Toxic epidermal necrolysis (severe skin reaction)
*   Hepatotoxicity (liver damage)
*   Anaphylaxis (severe allergic reaction)
*   New primary malignancies (development of new cancers)
*   Increased risk of secondary acute myeloid leukemia (a type of blood cancer)
*   Uveitis (eye inflammation)
*   Hypersensitivity reactions
*   Renal failure (kidney failure)


Any new or worsening symptom should be promptly reported to a healthcare provider.

### How it Works

Vemurafenib is a type of targeted therapy called a kinase inhibitor.  It works by selectively blocking the activity of mutated BRAF V600E protein. This mutated protein is a key driver of uncontrolled cell growth in certain cancers. By inhibiting the BRAF V600E protein, Vemurafenib helps slow or stop the growth of cancer cells.  It's important to note that it affects only the mutated form of the protein, minimizing effects on normal cells.

### Precautions

*   **Contraindications:** Vemurafenib is contraindicated in patients with hypersensitivity to the drug or its components.
*   **Drug Interactions:** Vemurafenib interacts with numerous medications, particularly those affecting the CYP3A4 enzyme system and those that prolong the QT interval on the ECG.  Consult with a healthcare professional about all other medications, supplements, or herbal remedies being taken to avoid potentially dangerous interactions.
*   **Pregnancy and Breastfeeding:** Vemurafenib can harm a developing fetus. Women of childbearing age should use effective contraception during treatment and for two weeks after the final dose. Breastfeeding should be avoided during treatment and for two weeks afterward.
*   **Specific Populations:**  Caution is warranted in patients with severe hepatic or renal impairment. Older adults may be more susceptible to adverse effects.


### FAQs

*   **Q: Can I take Vemurafenib with food?**  A: Vemurafenib can be taken with or without food.
*   **Q: What should I do if I miss a dose?** A: Take the missed dose as soon as you remember, unless it's within four hours of the next scheduled dose.  Don't double up on doses.
*   **Q: How should I store Vemurafenib?** A: Store Vemurafenib tablets at room temperature, away from moisture and light.
*   **Q: How long will it take to see results?** A: The time it takes to see results varies from person to person. Regular monitoring by your doctor is essential.
*   **Q: What if I experience side effects?** A: Report any side effects, especially serious ones, to your doctor immediately.  Dosage adjustments or treatment discontinuation may be necessary.
*   **Q: Is Vemurafenib right for everyone with melanoma?** A: No.  It's only effective for melanoma with the *BRAF* V600E mutation.  Genetic testing is essential before starting treatment.


**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional before starting or changing any medication.  The above information reflects current knowledge and understanding, and it's crucial to consult the most up-to-date prescribing information for the most current and comprehensive data.
